Methyl 4-(2-((5-(benzylthio)-1,3,4-thiadiazol-2-yl)thio)acetamido)benzoate

Catalog No. :
ACXSBB211
CAS No. :
477330-85-1
Molecular Formula :
C19H17N3O3S3
Molecular Weight :
431.56

IUPAC Name:methyl 4-(2-((5-(benzylthio)-1,3,4-thiadiazol-2-yl)thio)acetamido)benzoate

Methyl 4-(2-((5-(benzylthio)-1,3,4-thiadiazol-2-yl)thio)acetamido)benzoate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameMethyl 4-(2-((5-(benzylthio)-1,3,4-thiadiazol-2-yl)thio)acetamido)benzoate
IUPAC Namemethyl 4-(2-((5-(benzylthio)-1,3,4-thiadiazol-2-yl)thio)acetamido)benzoate
MDL No.MFCD03223701
Molecular FormulaC19H17N3O3S3
Molecular Weight431.56
SMILESO=C(OC)C1=CC=C(NC(CSC2=NN=C(SCC3=CC=CC=C3)S2)=O)C=C1
InChI KeyQGEXZSPJZYTYES-UHFFFAOYSA-N
SynonymSALOR-INT L244449-1EA;METHYL 4-((((5-(BENZYLTHIO)-1,3,4-THIADIAZOL-2-YL)THIO)ACETYL)AMINO)BENZOATE;Benzoic acid, 4-[[2-[[5-[(phenylmethyl)thio]-1,3,4-thiadiazol-2-yl]thio]acetyl]amino]-, methyl ester
CAS No.477330-85-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACXSBB211 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACKPLR230 route compound structure diagram
    ACKPLR2304858-36-0 In Stock
  4. Then
  5. ACXSBB211 route product structure diagram
    ACXSBB211477330-85-1
Inquiry

2. ACXSBB211 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACAQXN128 route compound structure diagram
    ACAQXN128619-45-4 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACXSBB211 route product structure diagram
    ACXSBB211477330-85-1
Inquiry

Comments (0)